T-CELLS ARE THE FOUNDATION OF IMMUNE HEALTH

T-cells are a primary type of lymphocyte, essential for adaptive immunity, which allows the immune system to remember and target previously encountered invaders. The two main types are: killer T-cells (CD8) which destroy infected or cancerous cells and helper T-cells (CD4) which tell other parts of the immune system to come help fight infections.

CD4 and CD8 comprise up to 75% of lymphocytes and serve as key indicators of immune system health.

Distribution of white blood cells subpopulation in human peripheral blood

Dr. Anthony Fauci - an American immunologist and a leading expert in infectious diseases. He has served as the Director of the National Institute of Allergy and Infectious Diseases (NIAID) since 1984, playing a key role in U.S. public health policy for decades.

Dr. Anthony Fauci - an American immunologist and a leading expert in infectious diseases. He has served as the Director of the National Institute of Allergy and Infectious Diseases (NIAID) since 1984, playing a key role in U.S. public health policy for decades.

LONGEVITY SECRETS FOUND IN T-CELLS

Scientists discovered a significant difference in the composition of T-cells, which play a key role in the immune system, between supercentenarian (110 years+) and adults in their 50-80s.

In particular, the share of CD4 T-cells (as a percentage of the total T-cells in the blood) of the supercentarians stood at about 25%. Among average people, the percentage is usually in the single digits.

We have validated the benefits of GPComplex® through the highest scientific rigor of clinical trial

BENEFITS of GPComplex® DISCOVERED THROUGH TWO DECADES OF RESEARCH

  • IMMUNE REGULATION*
  • ANTI-AGING*
  • ANTI-TUMOR*
  • Anti-INFLAMMATION*
  • ANTI-VIRAL*
  • ANTI-BACTERIAL*

42-day clinical trial involving 240 subjects on the effect of GPComplex® on immune function

55.1%

growth rate of helper T-cell count: CD4

53.9%

improvement in helper & killer T-cell ratio: CD4/CD8

35.9%

growth rate of T-cell count: CD3

  • Fatigue
  • Cough
  • Phlegm
  • Chest tightness
About This Clinical Trial

Phase II randomized, double blind, placebo controlled, multi-center clinical trial with 240 subjects

Research Objective

To evaluate the effectiveness and safety of GPComplex® in improving immune function in patients with chronic bronchitis

Participating Hospitals
  1. First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine
  2. Longhua Hospital affiliated with Shanghai University of Traditional Chinese Medicine
  3. Shanghai Municipal Hospital of Traditional Chinese Medicine affiliated with Shanghai University of Traditional Chinese Medicine
  4. First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
  5. Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

42-day clinical trial involving 480 men and women on the effect of GPComplex® on chronic bronchitis

30.4%

growth rate of helper T-cell count: CD4

33.6%

improvement in helper & killer T-cell ratio: CD4/CD8

24.4%

growth rate of T-cell count: CD3

  • Fatigue
  • Cough
  • Phlegm
  • Chest tightness
About This Clinical Trial

Phase III randomized, double blind, placebo controlled, multi-center clinical trial with 480 subjects

Research Objective

To evaluate the effect and safety of GPComplex® on increasing CD4, CD4/CD8, and CD3 in patients with chronic bronchitis, and improving major symptoms (cough, phlegm)

Participating Hospitals
  1. First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine
  2. Longhua Hospital affiliated with Shanghai University of Traditional Chinese Medicine
  3. Shanghai Municipal Hospital of Traditional Chinese Medicine affiliated with Shanghai University of Traditional Chinese Medicine
  4. First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
  5. Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
  6. Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine.

4-week observational study involving 32 men and women on the effect of GPComplex® on cancer-related fatigue

Lymphocytes count
T-cell count: CD3
Functional ability: KPS
Pain: Piper score
Fatigue (BFI)
About This Study

Single-arm, single-center, observational study with 22 women and 10 men

Research Objective

To evaluate the effects and safety of GPComplex® on immune function and on major symptoms of cancer-related fatigue

Participating Hospitals

Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Other in vivo and in vitro research studies on GPComplex®

Research Result
Anti-cancer
Suppressed tumor growth, activated CD4 and CD8, increased T-cell counts

Ayeka PA et. al. BMC Complement Altern Med. 2017
Anti-cancer
Exerted anti-tumor effects by affecting gut microbiome composition

Zhang X et. al. J Pharmacol Sci. 2018
Anti-cancer
Increased CD3 and CD4 count, promoted T-cell proliferation, enhanced the immune function

Tianjin Institute of Pharmaceutical Research
Cellular immunity
Improved delayed allergic reaction, enhanced T-cell function

Tianjin Institute of Pharmaceutical Research
Humoral immunity
Increased antibody (serum IgG level), enhanced humoral immunity

Tianjin Institute of Pharmaceutical Research
Anti-bacterial, anti-viral
Resisted bacterial and viral infections, enhanced immune function

Tianjin Institute of Pharmaceutical Research
Nonspecific immunity
Increase phagocytic activity, enhanced non-specific immune response

Tianjin Institute of Pharmaceutical Research